Research programme: opioid agonists - BTG

Drug Profile

Research programme: opioid agonists - BTG

Alternative Names: BTG-6001

Latest Information Update: 21 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CLL PHARMA
  • Developer BTG
  • Class
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Postoperative pain

Most Recent Events

  • 01 Jan 2013 Discontinued - Preclinical for Postoperative pain in United Kingdom (PO)
  • 12 Feb 2009 Preclinical development is ongoing in United Kingdom
  • 20 Feb 2007 Preclinical trials in Postoperative pain in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top